AstraZeneca Electrifies 80% of Global Fleet in Push for Net-Zero

AstraZeneca reaches 81.5% electric vehicle fleet in 2025

AstraZeneca reported that 81.5% of its global vehicle fleet was battery electric by 2025. The pharmaceutical company now operates more than 18,000 electric vehicles worldwide. However, the business fell short of its original target to transition its entire fleet to electric power where technically feasible.

The company cited vehicle supply constraints and charging infrastructure limitations in some markets as the main barriers. Nevertheless, AstraZeneca has deployed battery electric vehicles across more countries than any other participant in the EV100 initiative, according to its own disclosures.

This development matters because AstraZeneca was among the first major pharmaceutical companies to commit to large-scale fleet electrification. The business joined the EV100 initiative and pledged a fully electric vehicle fleet by 2025 as part of its broader Ambition Zero Carbon plan launched in 2020.

Five-year transition delivers 18,000 electric vehicles

AstraZeneca’s latest sustainability data show significant acceleration in fleet electrification over recent years. In 2023, battery electric vehicles represented 35% of the company’s fleet. This figure rose to 63% in 2024 before reaching 81.5% in 2025.

The transition was part of the company’s Ambition Zero Carbon strategy announced in 2020. At that time, AstraZeneca described switching to a fully electric vehicle fleet as moving “five years ahead of schedule.” The plan included three main commitments: zero carbon emissions from operations by 2025, a fully electric vehicle fleet by 2025 where technically feasible, and a carbon-negative value chain by 2030.

Despite missing the 100% target, the company has made substantial progress. More than 18,000 battery electric vehicles now operate across AstraZeneca’s global operations. The business has also worked to support this fleet with renewable electricity, aiming for 100% renewable electricity by the end of 2025.

The scale of deployment is notable. AstraZeneca reports that it has introduced battery electric vehicles in more markets than any other company participating in EV100. This global initiative brings together businesses committed to accelerating the transition to electric vehicles.

Supply chains and infrastructure create regional barriers

AstraZeneca’s sustainability disclosure marked the fleet electrification target as “not met” for 2025. The company identified two primary obstacles: vehicle supply constraints and charging infrastructure limitations in certain markets.

These barriers vary significantly by region. Some countries have well-developed electric vehicle supply chains, with multiple manufacturers offering commercial vehicles and established charging networks. Other markets face limited vehicle availability, particularly for specific commercial vehicle types that pharmaceutical companies require for field operations.

Charging infrastructure presents different challenges. Installing charging points requires electrical capacity, physical space, and often planning permissions. For a company operating across dozens of countries, infrastructure quality and availability differ substantially. Some regions have extensive public charging networks, while others have minimal provision outside major cities.

The situation reflects a common pattern in corporate decarbonization. Businesses can often achieve rapid progress in developed markets with mature electric vehicle ecosystems. Meanwhile, operations in emerging markets or regions with less developed infrastructure face longer timelines. This creates a gap between ambition and delivery, even when companies commit significant resources.

For AstraZeneca, the constraint appears to be external rather than financial or strategic. The company has demonstrated willingness to invest in fleet transition and has successfully electrified more than four-fifths of its vehicles. The remaining portion appears to be waiting on market conditions beyond the business’s direct control.

Renewable electricity supports charging infrastructure

AstraZeneca has linked its fleet electrification to renewable electricity procurement. The company aims for 100% renewable electricity by the end of 2025. This approach addresses a critical question about electric vehicle fleets: where does the electricity come from?

Using renewable electricity to charge battery electric vehicles reduces the carbon intensity of fleet operations. If vehicles charged using fossil-fuel-generated electricity, the emissions would simply shift from vehicle tailpipes to power stations. By contrast, renewable electricity allows the fleet to operate with minimal carbon emissions across the full energy chain.

This dual approach reflects wider thinking about corporate decarbonization. Electrification alone does not guarantee carbon reduction unless the electricity source is clean. Consequently, many businesses now combine fleet transition with renewable energy procurement, treating them as connected elements of the same strategy.

The pharmaceutical sector has particular operational requirements. Field teams need vehicles that can cover substantial distances, often to remote locations. Charging infrastructure must therefore be reliable, and vehicles must have sufficient range for daily operations. These practical considerations make renewable electricity and charging infrastructure essential enablers of fleet transition.

Fleet electrification delivers operational and strategic benefits

The shift to battery electric vehicles reduces direct fuel use and tailpipe emissions from company vehicles. For a global pharmaceutical business operating thousands of vehicles, this creates measurable carbon savings. However, the benefits extend beyond immediate emissions reduction.

Fleet transition demonstrates how procurement decisions can drive decarbonization. AstraZeneca’s vehicle purchasing affects manufacturers, charging infrastructure providers, and electricity suppliers. By committing to electric vehicles at scale, the company creates demand that supports market development. This matters particularly in regions where electric vehicle adoption remains low.

The approach also shows how businesses can use multiple levers together. AstraZeneca combined vehicle procurement, charging infrastructure investment, and renewable electricity contracts. Each element supports the others, creating a system that enables fleet operations with lower carbon intensity.

From a strategic perspective, early adoption builds knowledge and experience. AstraZeneca has now operated battery electric vehicles across diverse markets for several years. The company understands which vehicle types work in different contexts, how to manage charging infrastructure, and where supply chain constraints create obstacles. This knowledge has value beyond carbon reduction.

There are also commercial considerations. Public sector tenders increasingly include sustainability criteria. Supply chain partners face growing pressure to demonstrate carbon reduction. Operating a predominantly electric fleet provides evidence of environmental commitment that may influence customer and partner decisions.

What AstraZeneca’s experience shows about corporate fleet transition

• AstraZeneca reached 81.5% fleet electrification by 2025, representing more than 18,000 battery electric vehicles worldwide.
• The company missed its target of 100% electrification where technically feasible, citing vehicle supply constraints and charging infrastructure limitations in some markets.
• Fleet electrification accelerated rapidly from 35% in 2023 to 63% in 2024 and 81.5% in 2025, showing sustained momentum despite barriers.
• AstraZeneca deployed battery electric vehicles across more markets than any other EV100 participant, demonstrating the scale of global rollout.
• The transition forms part of the company’s Ambition Zero Carbon plan, which also targets zero carbon operations by 2025 and a carbon-negative value chain by 2030.
• Renewable electricity procurement supports fleet charging, with AstraZeneca aiming for 100% renewable electricity by the end of 2025.
• External constraints in vehicle supply and infrastructure, rather than internal commitment or investment, appear to be the primary barriers to full electrification.

Planning fleet transition in the current market

AstraZeneca’s experience offers useful reference points for other businesses considering fleet electrification. The company achieved substantial progress over five years, moving from a predominantly fossil-fuel fleet to more than 80% electric vehicles. At the same time, it encountered barriers that prevented complete transition within the target timeframe.

Several factors emerge as important for businesses planning similar transitions. First, vehicle availability varies significantly by market and vehicle type. Companies operating across multiple countries should expect different timelines in different regions. What is readily available in Western Europe or North America may have limited supply elsewhere.

Second, charging infrastructure requires advance planning. Installing charging points takes time, particularly at sites where electrical capacity needs upgrading. Businesses should assess infrastructure requirements early and factor in lead times for installation and grid connections. Public charging networks can supplement private infrastructure, but reliability and coverage vary by location.

Third, renewable electricity procurement affects the carbon impact of fleet transition. Businesses should consider how they will source electricity for vehicle charging. This may involve power purchase agreements, renewable energy certificates, or on-site generation. The approach will depend on company size, operational footprint, and local electricity markets.

Fourth, fleet transition connects to wider decarbonization goals. For AstraZeneca, vehicle electrification forms part of a broader carbon reduction strategy. Businesses should think about how fleet decisions fit with other sustainability commitments, including Scope 1, 2, and 3 emissions reduction targets.

For companies facing tender requirements or supply chain sustainability assessments, fleet composition may carry commercial significance. Many public sector contracts now include carbon reduction criteria. Similarly, large corporations increasingly ask suppliers about their environmental performance. An electrified fleet provides tangible evidence of climate action.

We support businesses with carbon reporting, net-zero planning, and compliance with sustainability requirements through our net-zero program for carbon reporting compliance. This includes helping companies understand how fleet decisions affect their carbon footprint and what reporting obligations apply to their operations.

Government policy and industry initiatives support transition

AstraZeneca’s fleet transition took place within a policy environment that increasingly supports electrification. The UK government has set a target to end sales of new petrol and diesel cars by 2030, with some hybrid vehicles permitted until 2035. This creates a clear timeline for automotive manufacturers and fleet operators.

Several government schemes support electric vehicle adoption. The plug-in vehicle grant has previously provided funding for eligible vehicles, though this has been scaled back for cars while continuing for vans and other commercial vehicles. The workplace charging scheme offers grants for businesses installing charging points at their premises.

Industry initiatives also play a role. The EV100, led by the Climate Group, brings together companies committed to accelerating electric vehicle adoption. Members pledge to transition their fleets and install charging infrastructure for staff and customers. This creates peer networks where businesses share experience and drive market development.

For pharmaceutical companies specifically, there are sector-wide sustainability commitments. Many businesses in this industry have announced science-based targets or net-zero pledges. Fleet electrification forms one element of meeting these commitments, particularly for Scope 1 emissions from company-owned vehicles.

The regulatory environment continues to develop. Carbon reporting requirements have expanded through the Streamlined Energy and Carbon Reporting framework. Larger companies must disclose energy use and emissions in annual reports. From 2024, new sustainability disclosure requirements affect more businesses. These create compliance obligations that make carbon data from fleet operations increasingly important.

Additionally, planning for upcoming regulations makes commercial sense. As policy tightens and carbon disclosure requirements expand, businesses with established low-carbon fleets will face less disruption. Early transition also allows companies to learn from experience and refine their approaches before regulations make change mandatory. More information on compliance requirements is available through our ESG compliance and carbon reporting services.

Finding detailed information on fleet electrification and targets

Businesses researching fleet transition and corporate sustainability commitments can access several authoritative sources. The UK government provides guidance on electric vehicles and charging infrastructure through the Department for Energy Security and Net Zero conversion factors, which help companies calculate emissions from different vehicle types and fuel sources.

The Climate Group maintains information about the EV100 initiative, including participant commitments and progress reports. This offers insight into how different companies approach fleet electrification and what targets they have set.

For carbon reporting methodology and standards, the Greenhouse Gas Protocol provides detailed guidance on measuring and reporting emissions from mobile sources. This includes how to account for fleet emissions under different scopes and what data companies need to collect.

The Society of Motor Manufacturers and Traders publishes regular data on electric vehicle registrations and market trends in the UK. This helps businesses understand vehicle availability and market development. The organisation’s reports provide context on supply chain conditions and infrastructure deployment across different regions.